Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Mengus, Chantal ^a   Le Magnen, Clémentine ^a   Trella, Emanuele ^a   Yousef, Kawa ^a   Bubendorf, Lukas ^b   Provenzano, Maurizio ^a,c   Bachmann, Alexander ^a   Heberer, Michael ^a   Spagnoli, Giulio C ^a   Wyler, Stephen ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 15; INTERLEUKIN 7; SERUM AMYLOID A; ACUTE PHASE PROTEIN; IL15 PROTEIN, HUMAN; IL7 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN TISSUE; INTERLEUKIN 15 GENE; INTERLEUKIN 2 GENE; INTERLEUKIN 21 GENE; INTERLEUKIN 7 GENE; MALE; MOLECULAR PATHOLOGY; ONCOGENE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; BLOOD; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; SOLUBILITY;

ACUTE-PHASE PROTEINS; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-15; INTERLEUKIN-7; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SOLUBILITY;

EID: 80053366231     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-162     Document Type: Article

References (64)

1. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100:1672-1694. 10.1093/jnci/djn389, 2639291, 19033571.
2. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007, 7:256-269. 10.1038/nrc2090, 17384581.
3. Ebelt K, Babaryka G, Figel AM, Pohla H, Buchner A, Stief CG, Eisenmenger W, Kirchner T, Schendel DJ, Noessner E. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 2008, 68:1-10. 10.1002/pros.20661, 17948280.
4. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, Pisa P. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006, 177:7398-7405.
5. Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 2007, 56:81-87.
6. Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, Tsang KY. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008, 14:1032-1040. 10.1158/1078-0432.CCR-07-2056, 18281535.
7. Culig Z. Cytokine disbalance in common human cancers. Biochim Biophys Acta 2011, 1813:308-314. 10.1016/j.bbamcr.2010.12.010, 21167870.
8. He YW, Malek TR. The structure and function of gamma c-dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis. Crit Rev Immunol 1998, 18:503-524.
9. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001, 97:14-32. 10.1182/blood.V97.1.14, 11133738.
10. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood 2002, 99:3892-3904. 10.1182/blood.V99.11.3892, 12010786.
11. Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 2005, 5:688-698. 10.1038/nri1688, 16138102.
12. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003, 3:269-279. 10.1038/nri1052, 12669018.
13. Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, Shrikant PA. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 2004, 173:900-909.
14. von Holzen U, Adamina M, Bolli M, Weber WP, Zajac P, Groeper C, Reschner A, Feder C, Schumacher R, Marti W, et al. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy. Int J Cancer 2005, 115:248-255. 10.1002/ijc.20858, 15688403.
15. Fewkes NM, Mackall CL. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J 2010, 16:392-398. 10.1097/PPO.0b013e3181eacbc4, 20693852.
16. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006, 29:313-319. 10.1097/01.cji.0000210386.55951.c2, 1473976, 16699374.
17. Sportes C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010, 16:727-735. 10.1158/1078-0432.CCR-09-1303, 2808195, 20068111.
18. Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 2005, 115:1177-1187. 1074679, 15841203.
19. Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci USA 2003, 100:3392-3397. 10.1073/pnas.0630592100, 152303, 12626740.
20. Rosenthal R, Groeper C, Bracci L, Adamina M, Feder-Mengus C, Zajac P, Iezzi G, Bolli M, Weber WP, Frey DM, et al. Differential responsiveness to IL-2, IL-7, and IL-15 common receptor gamma chain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients. J Immunother 2009, 32:252-261. 10.1097/CJI.0b013e3181998e03, 19242375.
21. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science 2009, 324:1569-1572. 10.1126/science.1174182, 2830017, 19423777.
22. Frohlich A, Kisielow J, Schmitz I, Freigang S, Shamshiev AT, Weber J, Marsland BJ, Oxenius A, Kopf M. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 2009, 324:1576-1580. 10.1126/science.1172815, 19478140.
23. Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009, 324:1572-1576. 10.1126/science.1175194, 2736049, 19443735.
24. Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 2009, 15:2123-2129. 10.1158/1078-0432.CCR-08-2663, 19276257.
25. Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008, 26:2034-2039. 10.1200/JCO.2007.14.5193, 18347008.
26. Chopra V, Dinh TV, Hannigan EV. Angiogenin, interleukins, and growth-factor levels in serum of patients with ovarian cancer: correlation with angiogenesis. Cancer J Sci Am 1996, 2:279-285.
27. Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, ten Hoor KA, Braid M, van der Zee AG, Daemen T, Nijman HW, Kast WM. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 2007, 13:2385-2391. 10.1158/1078-0432.CCR-06-1828, 17438097.
28. Trumper L, Jung W, Dahl G, Diehl V, Gause A, Pfreundschuh M. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol 1994, 5(Suppl 1):93-96.
29. Xie X, Ye D, Chen H, Lu W, Cheng B, Zhong H. Interleukin-7 and suppression of local peritoneal immunity in ovarian carcinoma. Int J Gynaecol Obstet 2004, 85:151-158. 10.1016/j.ijgo.2003.08.015, 15099777.
30. Al-Rawi MA, Rmali K, Watkins G, Mansel RE, Jiang WG. Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. Eur J Cancer 2004, 40:494-502. 10.1016/j.ejca.2003.10.016, 14962714.
31. Maeurer MJ, Walter W, Martin D, Zitvogel L, Elder E, Storkus W, Lotze MT. Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. Scand J Immunol 1997, 45:182-192. 10.1046/j.1365-3083.1997.d01-384.x, 9042431.
32. Kuniyasu H, Ohmori H, Sasaki T, Sasahira T, Yoshida K, Kitadai Y, Fidler IJ. Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res 2003, 9:4802-4810.
33. Pappa C, Miyakis S, Tsirakis G, Sfiridaki A, Alegakis A, Kafousi M, Stathopoulos EN, Alexandrakis MG. Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma. Cytokine 2007, 37:171-175. 10.1016/j.cyto.2007.02.022, 17446083.
34. Handisurya A, Steiner GE, Stix U, Ecker RC, Pfaffeneder-Mantai S, Langer D, Kramer G, Memaran-Dadgar N, Marberger M. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate 2001, 49:251-262. 10.1002/pros.10020, 11746271.
35. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, Gessl A, Lee C, Marberger M. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002, 52:43-58. 10.1002/pros.10084, 11992619.
36. Di CE, D'Antuono T, Pompa P, Giuliani R, Rosini S, Stuppia L, Musiani P, Sorrentino C. The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance. Clin Cancer Res 2009, 15:2979-2987. 10.1158/1078-0432.CCR-08-1951, 19366834.
37. Roato I, D'Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C, Delsedime L, Tizzani A, De LA, Isaia G, et al. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS ONE 2008, 3:e3627. 10.1371/journal.pone.0003627, 2574033, 18978943.
38. Martin I, Jakob M, Schafer D, Dick W, Spagnoli G, Heberer M. Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic joints. Osteoarthritis Cartilage 2001, 9:112-118. 10.1053/joca.2000.0366, 11237658.
39. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001, 25:386-401. 10.1006/meth.2001.1261, 11846608.
40. Hartwig D, Hartel C, Hennig H, Muller-Steinhardt M, Schlenke P, Kluter H. Evidence for de novo synthesis of cytokines and chemokines in platelet concentrates. Vox Sang 2002, 82:182-190. 10.1046/j.1423-0410.2002.00172.x, 12047512.
41. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
42. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995, 45:542-549. 10.1016/S0090-4295(99)80034-X, 7879350.
43. Feder-Mengus C, Wyler S, Hudolin T, Ruszat R, Bubendorf L, Chiarugi A, Pittelli M, Weber WP, Bachmann A, Gasser TC, et al. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur J Cancer 2008, 44:2266-2275. 10.1016/j.ejca.2008.05.023, 18619832.
44. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999, 38:199-207. 10.1002/(SICI)1097-0045(19990215)38:3<199::AID-PROS4>3.0.CO;2-H, 10068344.
45. Kaneti J, Winikoff Y, Zimlichman S, Shainkin-Kestenbaum R. Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol Res 1984, 12:239-241.
46. Pierce BL, Biggs ML, DeCambre M, Reiner AP, Li C, Fitzpatrick A, Carlson CS, Stanford JL, Austin MA. C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control 2009, 20:1193-1203. 10.1007/s10552-009-9320-4, 2846958, 19267250.
47. Prins RC, Rademacher BL, Mongoue-Tchokote S, Alumkal JJ, Graff JN, Eilers KM, Beer TM. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. Urol Oncol 2010,
48. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005, 64:92-100. 10.1002/pros.20219, 15666359.
49. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008, 8:279-289. 10.1038/nri2215, 2763408, 18340345.
50. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010, 10:826-837. 10.1038/nri2873, 21088683.
51. Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol 2004, 84:131-179.
52. Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2010, 171:571-582. 10.1093/aje/kwp406, 2842217, 20142396.
53. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005, 95:497-505. 10.1002/jcb.20477, 15838876.
54. Das D, Wojno K, Imperiale MJ. BK virus as a cofactor in the etiology of prostate cancer in its early stages. J Virol 2008, 82:2705-2714. 10.1128/JVI.02461-07, 2259013, 18160432.
55. Namiki K, Goodison S, Porvasnik S, Allan RW, Iczkowski KA, Urbanek C, Reyes L, Sakamoto N, Rosser CJ. Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS ONE 2009, 4:e6872. 10.1371/journal.pone.0006872, 2730529, 19721714.
56. Al-Rawi MA, Watkins G, Mansel RE, Jiang WG. Interleukin 7 upregulates vascular endothelial growth factor D in breast cancer cells and induces lymphangiogenesis in vivo. Br J Surg 2005, 92:305-310. 10.1002/bjs.4832, 15672426.
57. Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Tosato G. Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 1997, 233:231-237. 10.1006/bbrc.1997.6435, 9144429.
58. Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, Fauci AS. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008, 181:6738-6746.
59. Ebelt K, Babaryka G, Frankenberger B, Stief CG, Eisenmenger W, Kirchner T, Schendel DJ, Noessner E. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer 2009, 45:1664-1672. 10.1016/j.ejca.2009.02.015, 19318244.
60. Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009, 69:1694-1703. 10.1002/pros.21020, 2782577, 19670224.
61. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354. 10.1038/nature05115, 16921384.
62. Franceschini D, Paroli M, Francavilla V, Videtta M, Morrone S, Labbadia G, Cerino A, Mondelli MU, Barnaba V. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 2009, 119:551-564. 10.1172/JCI36604, 2648671, 19229109.
63. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 2007, 81:9249-9258. 10.1128/JVI.00409-07, 1951397, 17567698.
64. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, Hanson HL, Steinberg JP, Masopust D, Wherry EJ, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007, 81:2545-2553. 10.1128/JVI.02021-06, 1865979, 17182670.